Asubio Pharmaceuticals Inc has now opened its clinical trial for the SUN13837 molecule to include AIS A, B and C injury to the cervical spine. The company is currently working with 45 acute trauma centers throughout the United States and Canada and plans to increase that number to 55.
“SUN13837 is expected to provide neuroprotection from glutamate excito-toxicity and promote axonal outgrowth, which is often inhibited after spinal cord injury,” said Benjamin Levinson, M.D., Senior Director of Medical and Scientific Affairs at Asubio. The molecule has been without significant side effects in Phase 1 studies in healthy subjects.